Sharda Cropchem Limited (SHARDACROP) — Multibagger Analysis

AI research on 1 Expansion / Order-win announcement by Sharda Cropchem Limited since July 2026 — deal magnitude, revenue and EPS impact, execution risk, and the actual return since each announcement measured from the next trading day's open and benchmarked against the Nifty Smallcap 250.

Investor Presentation

29 July 2026 · Expansion · Possible · Pesticides / Agrochemicals - Indian · score 68/100

Deal

Deal value₹263 Cr

Deal vs businessQ1 FY27 capex of ₹263 Cr is ~5.0% of TTM revenue and ~51% of total FY26 capex

Size vs own revenue0.05×

Execution period3.0 yr

Fundamental gradeB

AI projections

Revenue uplift (yr1 / steady)4.0% / 15.0%

EPS uplift12.0%

Upside base / bull / bear35.0% / 71.0% / -20.0%

Horizon24-36 months

Realized market record

Entry — next-day open (30 Jul 2026)₹820.0

Latest close (16 Oct 2026)₹725.35

Return since-11.5%

α vs Smallcap 250-10.0%

Positives

High capital efficiency with ROCE of 32% and zero debt (net worth ~₹3,137 Cr).
Asset-light IP registration library expansion: total registrations reached 3,016 across 80+ countries with 1,047 pending dossiers.
Aggressive reinvestment: Q1 FY27 capex of ₹263 Cr represents over half of FY26 total capex, accelerating future dossier launches.
Promoter holding remains high and stable at 74.82%.
Significant exposure to high-margin regulated markets in Europe and NAFTA.

Risks

Q1 FY27 margin compression: PBT dropped 30% YoY despite 9% revenue growth, illustrating operational margin volatility.
100% reliance on third-party manufacturers (mostly in China) creates supply chain and duty vulnerability.
High sensitivity to foreign exchange volatility and global agrochemical price cycles.
Product mix volatility: volume growth often comes from lower-priced generic lines that compress gross margins.

Full AI brief

Sharda Cropchem (SHARDACROP) - Investment Analysis Report

Analysis Date: 2026-07-29
Current Price: ₹827.5 | Market Cap: ₹7,466 Cr | Trailing P/E: 11.0x | ROCE: 32.0%

1. Catalyst & Execution Math

Sharda Cropchem announced a Q1 FY27 capex outlay of ₹263 Cr, which constitutes ~51% of the total investing activities completed in FY26 (~₹515 Cr). Global registered dossiers increased to 3,016 with 1,047 applications pending.

Asset-Light Dossier Model: Capex is allocated toward IP dossiers rather than physical plants. A typical regulatory approval cycle in Europe/NAFTA takes 3 to 5 years.
Ramp-Aware Revenue Contribution:
Total TTM Revenue: ₹5,268 Cr.
Year 1 Incremental Revenue: ~₹210 Cr (+4.0% uplift) as active pending applications roll out.
Steady-State Annual Revenue Uplift (by Year 3): ~₹790 Cr (+15.0% cumulative uplift from current pipeline).
Margin & EPS Implications: While FY26 PAT reached a peak of ₹681 Cr (EPS ₹75.48), Q1 FY27 results released simultaneously show short-term margin compression (PBT down 30% YoY to ₹118.4 Cr). Steady-state PAT margin is modeled at ~11.5–12.5%, yielding a steady-state EPS uplift of ~12% above FY26 baseline.

2. Industry Capital Intensity & Growth Context

Industry: Generic Pesticides / Agrochemicals.
Capital Intensity: Medium (For Sharda, low fixed-asset intensity but high intangible asset / registration intensity).
Expected Industry CAGR: 8.0% - 9.0% globally for generic formulations as major active ingredients go off-patent.
Moat Sustainability: Sharda's regulatory registration barrier (3,016 active dossiers) creates strong regional distribution lock-in across 80+ countries.

3. Fundamental Quality & Financial Health

ROCE: 32.0% (Passed quality gate).
Balance Sheet: Debt-Free (D/E 0.00), Net Worth ~₹3,137 Cr.
Promoter Holding: High at 74.82% with no pledges.
Earnings Volatility: Historical earnings show high cyclicality (FY24 PAT was -₹23.6 Cr due to high inventory costs and price deflation, before recovering to ₹681 Cr in FY26).

4. Valuation Scenarios (24-36 Month Horizon)

Base Case (+35.0% Upside):
Revenue grows at 12-14% CAGR to ~₹6,800 Cr.
PAT margin stabilizes at 11.5% -> PAT ₹782 Cr -> EPS ₹86.6.
P/E re-rates mildly to 13.0x -> Target Price ₹1,125 (+35.0%).
Bull Case (+71.0% Upside):
Rapid dossier approvals and strong European volume growth drive Revenue to ~₹7,400 Cr.
Gross margins expansion yields 13.0% PAT margin -> PAT ₹962 Cr -> EPS ₹106.5.
P/E expands to 13.3x (industry median context 16.4x) -> Target Price ₹1,416 (+71.0%).
Bear Case (-20.0% Downside):
Chinese sourcing disruptions and price erosion push PAT down to ₹550 Cr -> EPS ₹61.0.
P/E compresses to 10.8x -> Target Price ₹660 (-20.0%).

5. Verdict Rationale

Sharda Cropchem is a POSSIBLE multibagger candidate (Score: 68/100). The asset-light regulatory registration engine generates strong return ratios (32% ROCE) and operates debt-free. However, cyclical margin swings and generic price sensitivity temper conviction from 'Strong Candidate' to 'Possible'.

Analysis as of 2026-07-29 (price ₹827.55) · AI research, not investment advice.

FollowTelegram

Verdicts and projections on this page are produced by an AI model from Sharda Cropchem Limited's public exchange filings and are not investment advice. "Return since" is measured from the opening price of the next trading day after each announcement to the latest available close, so it reflects a price an investor could actually have paid. See all analysed companies on Multibagger AI.